There is an urgent need among startups, SMEs and academic spin-offs for access to specialised production facilities in order to be able to make new treatments for serious diseases available to patients and clinical practice in a way that is safe and (cost) effective.
Anicells wants to support companies in the valorisation of their cell therapeutic research by developing and making available a GMP certified accelerator.
This is a full concept made up of (1) GMP certified lab facilities, (2) qualified personnel, (3) experts with knowledge of medical logistics, engineering and ‘lean-manufacturing’, (4) consultants with expertise in the laws and regulations on the interactions with the FAMHP and CAT and (5) business developers in order to support the utilisation plan.
In this co-creation model, the companies can translate their research into a cell-based therapeutic product, start up the initial clinical trials, optimise the production process, develop the logistics process and launch their implementation plan. The accelerator will be made available for SMEs, startups and spin-offs from various regions. As a result, Anicells has the potential to accelerate the valorisation of academic and industrial research in cell therapy and thus to facilitate the marketing of cell therapy products via spin-off pathways.
With the support of ERDF Flanders (European Regional Development Fund) our aim is to reinforce –through the infrastructure, training modules for cell manipulation technologies as well as the cell-based therapy cluster – the innovation ecosystem around cell therapy and the competitive position and anchoring of Flemish companies.